Related Experiment Video
Updated: Aug 9, 2026
07:59
Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads
Published on: July 21, 2017
[Metabolic effect of lipostabil-forte]
Kardiologiia
|October 1, 1989
Summary
Lipostabil-Forte, rich in unsaturated fatty acids, significantly improved lipid profiles and thyroid function in coronary heart disease patients. This therapy also reversed hyperinsulinemia, enhancing overall cardiovascular health.
Area of Science:
- Cardiovascular Science
- Nutritional Biochemistry
Context:
- Coronary heart disease (CHD) poses a significant global health burden.
- Dyslipidemia, insulin resistance, and thyroid dysfunction are common comorbidities in CHD patients.
- Current therapeutic strategies for CHD often require multifaceted approaches.
Purpose:
- To investigate the effects of Lipostabil-Forte, a supplement containing unsaturated fatty acids, on key metabolic and hormonal markers in patients with coronary heart disease.
- To evaluate the impact of this intervention on serum lipids, plasma and erythrocyte phospholipid fractions, immunoreactive insulin, and thyroid hormones.
Summary:
- Lipostabil-Forte administration led to a significant reduction in serum triglycerides.
- The therapy increased relative erythrocyte phospholipid levels and plasma and erythrocyte phosphocholine.
- Improvements included the reversal of hyperinsulinemia and enhanced thyroid function.
Impact:
- Lipostabil-Forte demonstrates potential as a therapeutic agent for managing dyslipidemia and associated metabolic disturbances in coronary heart disease.
- This intervention may offer a complementary approach to improve cardiovascular health by addressing multiple risk factors simultaneously.
- Further research can explore the long-term efficacy and optimal dosage of Lipostabil-Forte in cardiovascular patient populations.
Related Concept Videos
01:06Lipid Digestion
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
01:06Fats as Energy Storage Molecules
Triglycerides are a form of long-term energy storage molecules. They are made of glycerol and three fatty acids. To obtain energy from fat, triglycerides must first be broken down by hydrolysis into their two principal components, fatty acids and glycerol. This process, called lipolysis, takes place in the cytoplasm. The resulting fatty acids are oxidized by β-oxidation into acetyl-CoA, which is used by the Krebs cycle. The glycerol that is released from triglycerides after lipolysis directly...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...